Investitionsthese
EQT Life Sciences invests in inventors with transformative ideas to improve patient lives, providing capital and strategic support across clinical, operational, financial, and commercial domains.
Investitionsphase
Early-stage to Growth-stage (Seed, Series A, Series B, Series C)
Bevorzugte Reifephase für die erste Finanzierung.
Sektoren & Themen
Biotech, Medical Devices, Pharmaceuticals, Diagnostics, Digital Health
Thematische Schwerpunkte und Zielmarktsegmente von Interesse.
Ticketgröße
€10.000.000 - €60.000.000
Standard-Finanzierungsbetrag pro Runde.
Outreach & Dossier-Analysen
Verifiziertes E-Mail-Muster
Analysen-Scorecard der Investitionsthese
Unser KI-Analyzer hat Portfolio-Unternehmen gescannt und verifizierte Übereinstimmungen berechnet...
Investment Team (35)
A
Adam Scheid
Partner
A
Adil Haque
Partner, Head of Institutional Product Management
A
Albert Gustafsson
Partner & COO Private Capital Europe & North
A
Anne Portwich
Partner
A
Arno de Wilde
Managing Director at EQT Life Sciences
B
B. V. G.
Vice President Risk Management
C
Carl Svantesson
Partner
C
Christoph Broja
Partner
C
Cillian King
Partner
D
Dr René Kuijten
Managing Partner
D
Drew Burdon
Partner
F
F. A.
General Partner
F
Felice Verduyn - Van Weegen
Investment Professional
F
Fouad Azzam
Partner at EQT Life Sciences
G
Geraldine O'Keeffe
Partner
I
Isabel de Paoli
Partner
J
Joachim (JR) Rothe, PhD
Managing Partner
J
John de Koning, PhD
Partner
K
Katherine Kitson
Director, Impact
K
Kaushik Subramanian
Partner
L
Lars Jörnow
Partner
L
Lennart Blecher
Chairperson of EQT Real Assets
M
Mark Wegter
Partner, EQT Life Sciences
M
Martijn Keijwegt
Founder, Owner
M
Martijn Kleijwegt
Investment Advisor
M
Michael Bauer
Partner, Co-Head of EQT's Global Healthcare sector team
P
Philip Scheltens
Partner, Head of Dementia Fund
R
René Kuijten
Partner
R
René R. Kuijten
Partner, Head of EQT Life Sciences
R
Rudy Dekeyser
Partner, Head of Health Economic Funds
S
Sandra Malmberg
Partner
T
Ted Persson
Partner
T
Thomas von Koch
Partner
V
Vincent Brichard
Board member at FoRx Therapeutics
d
de Jong
Partner
